We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Recommended Testing for Legionnaires' Disease Misses Cases

By LabMedica International staff writers
Posted on 18 Oct 2011
The guidelines concerning testing patients for possible community-acquired pneumonia due to Legionella may underestimate the number of cases being seen by clinicians.

These guidelines recommend testing for the urine antigen of Legionella in patients with any of the following: severe pneumonia requiring intensive care unit admission, failure of outpatient antibiotics, active alcohol abuse, history of travel within previous two weeks, or pleural effusion.

Doctors at the Rhode Island Hospital (Providence, RI, USA) carried out a retrospective study that identified nearly 4,000 patients with a primary or secondary diagnosis of pneumonia in an 18-month period. More...
Of these, 1,406 patients (35%) had a Legionella urine antigen test and/or Legionella culture as follows: 1,251 had a urine antigen test alone; 49 had a Legionella culture alone; and 106 had both a Legionella culture and urine antigen test. During the same time period, 626 patients underwent bronchoscopy and had bronchoscopic specimens sent to the microbiology laboratory for culture, 277 (44%) of whom had Legionella testing done as follows: 122 had a Legionella culture alone; 31 had a urine antigen test alone; and 124 had both a Legionella culture and urine antigen test.

The study found that if testing was only done in patients felt to be at increased risk of Legionnaires' disease based on the current guidelines, more than 40% of Legionella cases could be missed based on this single-center study. Nearly all of the cases were community-acquired and all cases were L. pneumophila serogroup 1. Thirty-six of the 37 cases were diagnosed solely by urine antigen testing. This suggests that cases of Legionnaires' disease due to other serogroups may have been missed because Legionella culture was underutilized. The scientists suggest more widespread testing for Legionella in patients admitted to hospitals with pneumonia.

Leonard Mermel, DO, medical director of the epidemiology and infection control department at Rhode Island Hospital, said," This single-center study suggests that current recommendations for Legionella testing will result in missed cases. More widespread testing will identify additional cases allowing focused antimicrobial therapy and will alert public health officials of such Legionella cases.” The study was published on September 7, 2011, in the Biomedcentral's online journal BMC Infectious Diseases.

Related Links:
Rhode Island Hospital



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.